eXoZymes EV/FCF

What does eXoZymes do? Invizyne Technologies Inc develops the SimplePath platform, a series of enzyme-based biomanufacturing systems that use natural processes to convert starting materials into desired end-products. The company targets natural ingredients including cannabinoids, flavor enhancers, fragrances, nutraceuticals, and organic compounds, as well as pharmaceuticals and chemicals like commodity and specialty chemicals. Pre-revenue and in development stage, Invizyne focuses on sustainable biomanufacturing through cell-free technology, with no current revenue streams. The SimplePath platform consists of modular enzyme systems designed for specific biocatalytic conversions. Each module combines one or more enzymes to perform defined chemical transformations, enabling the production of natural ingredients, pharmaceuticals, and specialty chemicals. Invizyne's technology aims to guide sustainable biomanufacturing by leveraging natural processes without requiring live cells. Invizyne Technologies Inc is a US-based biotechnology company headquartered in Monrovia, California, with 29 full-time employees. The company went public via IPO on November 13, 2024, but remains pre-revenue, focusing solely on development of its SimplePath platform for enzyme-based manufacturing solutions. eXoZymes is one of the most popular companies on Eulerpool.